Pathophysiology: Heart Failure. Objectives. Heart Failure. Mat Maurer, MD Associate Professor of Clinical Medicine

Similar documents
1 Congestive Heart Failure & its Pharmacological Management

1p36 and the Heart. John Lynn Jefferies, MD, MPH, FACC, FAHA

Universitätsklinik für Kardiologie. Test. Thomas M. Suter Akute Herzinsuffizienz Diagnostik und Therapie 1

Milwaukee School of Engineering Case Study: Factors that Affect Blood Pressure Instructor Version

Cardiovascular System & Its Diseases. Lecture #4 Heart Failure & Cardiac Arrhythmias

INTRODUCTION TO EECP THERAPY

Heart Failure EXERCISES. Ⅰ. True or false questions (mark for true question, mark for false question. If it is false, correct it.

Inpatient Heart Failure Management: Risks & Benefits

ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)

2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation.

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease

HYPERTROPHIC CARDIOMYOPATHY

Acute heart failure may be de novo or it may be a decompensation of chronic heart failure.

Blood Pressure. Blood Pressure (mm Hg) pressure exerted by blood against arterial walls. Blood Pressure. Blood Pressure

Exchange solutes and water with cells of the body

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Anaesthesia and Heart Failure

Heart Failure: Diagnosis and Treatment

James F. Kravec, M.D., F.A.C.P

Perioperative Cardiac Evaluation

SPECIALTY : CARDIOLOGY CLINICAL PROBLEM: HEART FAILURE

Hypertension and Heart Failure Medications. Dr William Dooley

Chapter 16. Learning Objectives. Learning Objectives 9/11/2012. Shock. Explain difference between compensated and uncompensated shock

Treatment of cardiogenic shock

Cardiovascular diseases. pathology

Heart Disease: Diagnosis & Treatment

Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity

Cardiology ICD-10-CM Coding Tip Sheet Overview of Key Chapter Updates for Cardiology

Atrial Fibrillation Management Across the Spectrum of Illness

Atrial Fibrillation Based on ESC Guidelines. Moshe Swissa MD Kaplan Medical Center

Potential Causes of Sudden Cardiac Arrest in Children

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension

Vascular System The heart can be thought of 2 separate pumps from the right ventricle, blood is pumped at a low pressure to the lungs and then back

Inotropes/Vasoactive Agents Hina N. Patel, Pharm.D., BCPS Cathy Lawson, Pharm.D., BCPS

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

HEART HEALTH WEEK 3 SUPPLEMENT. A Beginner s Guide to Cardiovascular Disease HEART FAILURE. Relatively mild, symptoms with intense exercise

STAGES OF SHOCK. IRREVERSIBLE SHOCK Heart deteriorates until it can no longer pump and death occurs.

PULMONARY HYPERTENSION. Charles A. Thompson, M.D., FACC, FSCAI Cardiovascular Institute of the South Zachary, Louisiana

Section Four: Pulmonary Artery Waveform Interpretation

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

HYPERTENSION ASSOCIATED WITH RENAL DISEASES

Managing Mitral Regurgitation: Repair, Replace, or Clip? Michael Howe, MD Traverse Heart & Vascular

Ischemic Heart Disease: Angina Pectoris

Pulmonary Artery Hypertension

How To Understand What You Know

Management of the Patient with Aortic Stenosis undergoing Non-cardiac Surgery

Vasopressors. Judith Hellman, M.D. Associate Professor Anesthesia and Perioperative Care University of California, San Francisco

INHERIT. The Lancet Diabetes & Endocrinology In press

ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY. Guidelines for Use of Intravenous Isoproterenol

Listen to your heart: Good Cardiovascular Health for Life

Heart Failure: Nursing Assessment and Care

UPMC HEALTH PLAN MANAGEMENT OF HEART FAILURE WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION: CLINICAL PRACTICE GUIDELINE

Geriatric Cardiology: Challenges and Strategies

Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL

Anatomi & Fysiologi The cardiovascular system (chapter 20) The circulation system transports; What the heart can do;

HEART FAILURE ROBERT SOUFER, M.D.

Cardiovascular Disease and Maternal Mortality what do we know and what are the key questions?

ACLS PHARMACOLOGY 2011 Guidelines

Procedure for Inotrope Administration in the home

The new Heart Failure pathway

Atrial Fibrillation Peter Santucci, MD Revised May, 2008

Starling s Law Regulation of Myocardial Performance Intrinsic Regulation of Myocardial Performance

Automatic External Defibrillators

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa Objectives. No disclosures, no conflicts

There are few clinical syndromes that have undergone both the conceptual. Pathophysiology of Congestive Heart Failure

Congestive heart failure (CHF) is a. Diastolic Heart Failure. By Michel D Astous, MD, FRCPC

Note: The left and right sides of the heart must pump exactly the same volume of blood when averaged over a period of time

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Renovascular Hypertension

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3

Update on Small Animal Cardiopulmonary Resuscitation (CPR)- is anything new?

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

Slowing Heart Failure Progression: Optimal Treatment of Mild Heart Failure

Circulatory System Review

CONGESTIVE HEART FAILURE AND PUBLIC HEALTH Marwan Nasif, MD, Alaa Alahmad, MD

Advanced Heart Failure & Transplantation Fellowship Program

A. Begin diuretics B. Begin digoxin C. Begin B-blockers D. Endomyocardial biopsy E. None of the above

Congestive Heart Failure

Traumatic Cardiac Tamponade. Shane KF Seal 19 November 2003 POS

Diagnosis Code Crosswalk : ICD-9-CM to ICD-10-CM Cardiac Rhythm and Heart Failure Diagnoses

Preoperative Laboratory and Diagnostic Studies

Atrial Fibrillation and Heart Failure: A Cause or a Consequence

Sir Muir Gray, Director,

Hypertension and Diabetes

LIVING WELL WITH HEART FAILURE

CorCap Cardiac Support Device Patient Information Booklet

Symptom management: heart failure. Objectives. Epidemiology of advanced heart failure

ECG may be indicated for patients with cardiovascular risk factors

Renal Blood Flow GFR. Glomerulus Fluid Flow and Forces. Renal Blood Flow (cont d)

Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements

Drug Treatment in Type 2 Diabetes with Hypertension

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra

Quiz 5 Heart Failure scores (n=163)

Provider Checklist-Outpatient Imaging. Checklist: Nuclear Stress Test, Thallium/Technetium/Sestamibi (CPT Code )

TABLE 1 Clinical Classification of AF. New onset AF (first detected) Paroxysmal (<7 days, mostly < 24 hours)

2015 RN.ORG, S.A., RN.ORG, LLC

Version Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen

38 year old female with mild obesity. She is planning an exercise program to loose weight. She has no other known risk factors for CAD.

Sign up to receive ATOTW weekly

Transcription:

Pathophysiology: Heart Failure Mat Maurer, MD Associate Professor of Clinical Medicine Objectives At the conclusion of this seminar, learners will be able to: 1. Define heart failure as a clinical syndrome 2. Define and employ the terms preload, afterload, contractilty, remodeling, diastolic dysfunction, compliance, stiffness and capacitance. 3. Describe the classic pathophysiologic steps in the development of heart failure. 4. Delineate four basic mechanisms underlying the development of heart failure 5. Interpret pressure volume loops / Starling curves and identify contributing mechanisms for heart failure state. 6. Understand the common methods employed for classifying patients with heart failure. 7. Employ the classes and stages of heart failure in describing a clinical scenario Heart Failure Not a disease A syndrome From "syn meaning "together and "dromos" meaning "a running. A group of signs and symptoms that occur together and characterize a particular abnormality. Diverse etiologies Several mechanisms 1

Heart Failure: Definitions An inability of the heart to pump blood at a sufficient rate to meet the metabolic demands of the body (e.g. oxygen and cell nutrients) at rest and during effort or to do so only if the cardiac filling pressures are abnormally high. A complex clinical syndrome characterized by abnormalities in cardiac function and neurohormonal regulation, which are accompanied by effort intolerance, fluid retention and a reduced longevity A complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. Epidemiology Heart Failure: The Problem 3.5 million in 1991, 4.7 million in 2000, estimated 10 million in 2037 Incidence: 550,000 new cases/year Prevalence: 1% ages 50--59, >10% over age 80 More deaths from HF than from all forms of cancer combined Most common cause for hospitalization in age >65 Heart Failure Paradigms 2

Heart Failure: Classifications Right vs. Left Sided Cardiac vs. Non-cardiac Systolic vs. Diastolic Dilated vs. Hypertrophic vs. Restrcitive Heart Failure Compensated vs. Decompensated Acute vs. Chronic Forward vs. Backward High vs. Low Output Tension (g) Cardiac Muscle Function Preload Afterload Contractility d Tension (g) b b ΔL ΔL a d b g a c c e a d a Muscle Length (mm) Muscle Length (mm) Muscle Length (mm) Tension (g) +norepinephrine f The length of a cardiac muscle fiber prior to the onset of contraction. Frank Starling The force against which The force of contraction a cardiac muscle fiber independent of preload must shorten. and afterload. Isotonic Contraction Inotropic State From Muscle to Chamber 3

The Pressure Volume Loop Diastole Systole The Pressure Volume Loop P es Pressure ESPVR Preload EDPVR Volume Compliance/Stiffness vs Capacitance 4

Afterload (Arterial Properties) Ea (Arterial Elastance) If TPR = [MAP - CVP] / CO, and CO = SV * HR Substituting the second equation into the first we obtain: TPR = [MAP - CVP] / (SV*HR) Making two simplifying assumptions. 1. CVP is negligible compared to MAP. 2. MAP is approximately equal to the end-systolic pressure in the ventricle (Pes). Then, TPR = Pes / (SV*HR) Which can be rearranged to: Pes/SV TPR * HR. Cardiac Chamber Function Preload Afterload Contractility EDV EDP Wall stress at end diastole Aortic Pressure Total peripheral resistance Arterial impedance Wall stress at end systole Pressure generated at given volume. Inotropic State Frank Starling Curves Hypotension Pulmonar y Congestio n 5

Pathophysiology - PV Loop Pathophysiology of Heart Failure Myocardial Insult/Stimuli/Damage Pump dysfunction Activation of neurohormones Catecholamines Angiontensin II Cytokines Remodeling Hypertrophy Fibrosis Apoptosis Neurohormonal Activation in Heart Failure Myocardial injury to the heart (CAD, HTN, CMP, valvular disease) Initial fall in LV performance, wall stress Activation of RAS and SNS Remodeling and progressive worsening of LV function Morbidity and mortality Arrhythmias Pump failure RAS, renin-angiotensin system; SNS, sympathetic nervous system. Fibrosis, apoptosis, hypertrophy, cellular/molecular alterations, myotoxicity Peripheral vasoconstriction Sodium retention Hemodynamic alterations Heart failure symptoms Fatigue Activity altered Chest congestion Edema Shortness of breath 6

Neurohormonal Activation in Heart Failure Angiotensin II Norepinephrine Hypertrophy, apoptosis, ischemia, arrhythmias, remodeling, fibrosis Morbidity and Mortality Adrenergic Pathway in Heart Failure Progression CNS sympathetic outflow Vascular sympathetic activity Cardiac sympathetic activity Renal sympathetic activity b 1 b 2 α 1 α 1 b 1 α 1 Myocyte hypertrophy Myocyte injury Increased arrhythmias Vasoconstriction Activation of RAS Sodium retention Disease progression Neurohormonal Balance in Heart Failure 7

Neurohormones in Heart Failure Myocardial Injury Fall in LV Performance Activation of RAAS and SNS (endothelin, AVP, cytokines) Myocardial Toxicity Change in Gene Expression ANP BNP Peripheral Vasoconstriction Sodium/Water Retention Morbidity and Mortality Remodeling and Progressive Worsening of LV Function HF Symptoms Shah M et al. Rev Cardiovasc Med. 2001;2(suppl 2):S2 Pathophyisiology of myocardial remodeling: Insult / Remodeling Stimuli Wall Stress Cytokines Neurohormones Oxidative stress Increased Wall Stress Myocyte Hypertrophy Altered interstitial matrix Fetal Gene Expression Altered calcium handling proteins Myocyte Death Ventricular Enlargement Diastolic Dysfunction Systolic Dysfunction Response Salt and water retention Acute and Chronic Responses Benefits and Harm Short-term Effects (mainly adaptive; hemorrhage, acute heart failure) Augments preload Long-term Effects (mainly deleterious; chronic heart failure) Pulmonary congestion, anasarca Vasoconstriction Maintains pressure for perfusion of vital organs (brain, heart) Exacerbates pump dysfunction, increases cardiac energy expenditure Sympathetic stimulation Cytokine activation Hypertrophy Increased collagen Increases heart rate and ejection Vasodilatation Unloads individual muscle fibers May reduce dilatation Increases energy expenditure Skeletal muscle catabolism, deterioration of endothelial function, impaired contraction, LV remodeling. Deterioration and death of cardiac cells: cardiomyopathy of overload Impairs relaxation 8

Laplace s Law Where P = ventricular pressure, r = ventricular chamber radius and h = ventricular wall thickness h Remodeling Concentric vs. Eccentric Ventricular Remodeling 9

Pathophysiology of Heart Failure Four Basic Mechanisms 1. Increased Blood Volume (Excessive Preload) 2. Increased Resistant to Blood Flow (Excessive Afterload) 3. Decreased contractility 4. Decreased Filling Aortic Regurgitation Increased Blood Volume AI + Neurohormones AI + Remodeling Na Retention Vasoconstriction Ventricular Remodeling Etiologies Mitral Regurgitation Aortic Regurgitation Volume Overload Left to Right Shunts Chronic Kidney Disease Parameter BP (mm Hg) SV (ml) Cardiac Output (L/min) PCWP (mm Hg) Normal 140/75 64 3.8 10 AI 128/50 80 3.0 15 AI+Neuro- Hormones 130/50 82 4.3 25 AI + Remodeling 104/45 63 2.6 20 Hypertension Increased Afterload HTN + DD HTN + DD + HF Ea Diastolic Dysfunction Na Retention Vasoconstriction Remodeling Etiologies Aortic Stenosis Aortic Coarctation Hypertension Parameter BP (mm Hg) SV (ml) Cardiac Output (L/min) Normal 131/76 57 4.0 HTN 150/100 52 3.6 HTN + DD 140/92 49 3.4 HTN + Heart failure 161/105 57 4.0 PCWP (mm Hg) 10 10 13 23 10

MI Decreased Contractility MI + Heart Failure MI + Remodeling Na Retention Vasoconstriction Ventricular Remodeling Etiologies Ischemic Cardiomyopathy Myocardial Infarction Myocardial Ischemia Myocarditis Parameter BP (mm Hg) Normal 124/81 MI 80/40 90/54 Toxins Anthracycline Alcohol Cocaine SV (ml) Cardiac Output (L/min) PCWP (mm Hg) 60 4.2 12 42 3.0 17 46 3.2 25 MI + Neurohormones MI + Remodeling 87/44 46 3.2 23 Normal Decreased Filling HCM HCM + HF Ventricular Remodeling Na Retention Vasoconstriction Etiologies Mitral Stenosis Constriction Restrictive Cardiomypoathy Cardiac Tamponade Hypertrophic Cardiomyopathy Infiltrative Cardiomyopathy Parameter BP (mm Hg) SV (ml) Cardiac Output (L/min) PCWP (mm Hg) Normal 124/81 63 4.4 10 HCM 95/47 50 3.5 17 HCM + HF 105/53 55 3.8 26 Part II 11

Heart Failure: Classifications Right vs. Left Sided Cardiac vs. Non-cardiac Systolic vs. Diastolic Dilated vs. Hypertrophic vs. Restrcitive Heart Failure Compensated vs. Decompensated Acute vs. Chronic Forward vs. Backward High vs. Low Output Types of Heart Failure SHF Diastolic Pathophysiology Demographics 1 Cause Impaired Contraction All ages Coronary Artery Disease Impaired filling > 60 years Hypertension Systolic Versus Diastolic Failure Systolic Dysfunction Contractility Normal Diastolic Dysfunction Pressure Pressure Pressure Capacitance Volume Volume Volume 12

Systolic Versus Diastolic Failure Heart Failure: Classifications Right vs. Left Sided Cardiac vs. Non-cardiac Systolic vs. Diastolic Dilated vs. Hypertrophic vs. Restrcitive Heart Failure Compensated vs. Decompensated Acute vs. Chronic Forward vs. Backward High vs. Low Output Decompensated Heart Failure 13

Heart Failure: Classifications Right vs. Left Sided Cardiac vs. Non-cardiac Systolic vs. Diastolic Dilated vs. Hypertrophic vs. Restrictive Heart Failure Compensated vs. Decompensated Acute vs. Chronic Forward vs. Backward High vs. Low Output High vs. Low Output Failure Causes: Anemia Systemic arteriovenous fistulas Hyperthyroidism Beriberi heart disease Paget disease of bone Glomerulonephritis Polycythemia vera Carcinoid syndrome Obesity Anemia Multiple myeloma Pregnancy Cor pulmonale Polycythemia vera Heart Failure: Classifications Right vs. Left Sided Cardiac vs. Non-cardiac Systolic vs. Diastolic Dilated vs. Hypertrophic vs. Restrictive Heart Failure Compensated vs. Decompensated Acute vs. Chronic Forward vs. Backward High vs. Low Output 14

Dilated vs. Hypertrophic vs. Restrictive Type Dilated Hypertrophic Restrictive Definition Dilated left/both ventricle(s) with impaired contraction Left and/or right ventricular hypertrophy Restrictive filling and reduced diastolic filling of one/both ventricles, Normal/near normal systolic function Sample Etiologies Ischemic, idiopathic, familial, viral, alcoholic, toxic, Familial valvular with autosomal dominant inheritance Idiopathic, amyloidosis, endomyocardial fibrosis Dilated vs. Hypertrophic vs. Restrictive Clinical Manifestations Symptoms Reduced exercise tolerance Shortness of breath Congestion Fluid retention Difficulty in sleeping Weight loss 15

Diagnosis of heart failure Physical examination Chest X ray EKG Echocardiogram Blood tests: Na, BUN, Creatinine, BNP Exercise test MRI Cardiac catheterization NYHA Classification I II III IV Class Mild Mild Moderate Severe Patient Symptoms No limitation of physical activity No undue fatigue, palpitation or dyspnea Slight limitation of physical activity Comfortable at rest Less than ordinary activity results in fatigue, palpitation, or dyspnea Marked limitation of physical activity Comfortable at rest Less than ordinary activity results in fatigue, palpitation, or dyspnea Unable to carry out any physical activity without discomfort Symptoms of cardiac insufficiency at rest Physical activity causes increased discomfort ACC/AHA Staging System STAGE A High risk for developing HF STAGE B Asymptomatic LV dysfunction STAGE C Past or current symptoms of HF STAGE D End-stage HF Hunt, et al. J Am Coll Cardiol. 2001; 38:2101-2113. 16

ACC/AHA Staging System A B C D Stage High risk for developing heart failure Asymptomatic heart failure Symptomatic heart failure Refractory end-stage heart failure Patient Description Hypertension Coronary artery disease Diabetes mellitus Family history of cardiomyopathy Previous myocardial infarction Left ventricular systolic dysfunction Asymptomatic valvular disease Known structural heart disease Shortness of breath and fatigue Reduced exercise tolerance Marked symptoms at rest despite maximal medical therapy (e.g., those who are recurrently hospitalized or cannot be safely discharged from the hospital without specialized interventions) Goals of Treatment 1. Identification and correction of underlying condition causing heart failure. 2. Elimination of acute precipitating cause of symptoms. 3. Modulation of neurohormonal response to prevent progression of disease. 4. Improve long term survival. Etiologies Ischemic cardiomyopathy Valvular cardiomyopathy Hypertensive cardiomyopathy. Inflammatory cardiomyopathy Metabolic cardiomyopathy General system disease Muscular dystrophies. Neuromuscular disorders. Sensitivity and toxic reactions. Peripartal cardiomyopathy 17

Percipients /Associated Factors Inappropriate reduction in the intensity of treatment, including Dietary sodium restriction, Physical activity reduction, Drug regimen reduction, or, most commonly, a combination of these measures. Ischemia Hypertension Anemia Volume Overload Increased Metabolic Demand Infection Thyroid Disease Arrhythmia Asthma/COPD Targets of Treatment Standard Pharmacological Therapy ACE inhibitors Angiotensin Receptor Blockers Beta Blcokers Diuretics Aldosterone Antagonists Statins Vasodilators Inotropes A B C D Stage High risk for developing heart failure Asymptomatic heart failure Symptomatic heart failure Refractory end-stage heart failure Treatment Patient Treatment Hypertension Optimal pharmacologic therapy (OPT) Coronary artery disease Aspirin, ACE inhibitors, statins, b-blockers, a-b-blockers Diabetes mellitus (carvedilol) diabetic therapy Family history of cardiomyopathy OPT Previous myocardial infarction ICD Left if left ventricular systolic (LV) dysfunction (systolic) present Asymptomatic valvular disease OPT Known structural heart disease ICD Shortness if LV dysfunction of breath and (systolic) fatigue present CRT Reduced (if QRS exercise wide, LVEF 35%) tolerance OPT Marked symptoms at rest despite maximal Intermittent medical therapy IV inotropes (e.g., those who are recurrently ICD hospitalized as a bridge or to cannot transplantation be safely discharged from CRT the hospital without specialized interventions) Other devices (LVAD, pericardial restraint) 18

Treatment of Acute Heart Failure ACC/AHA Staging System Summary Complex Clinical Syndrome Multiple Etiologies and Classification Systems Physiologic Understanding Essential http://www.columbia.edu/itc/hs/medical/heartsim/ 19

20